Study highlights the significance of measurable residual disease in predicting outcomes and guiding treatment in pediatric leukemia

Cancer cells that remain after initial (induction) chemotherapy, called measurable residual disease (MRD), help predict outcomes for children with leukemia. In collaboration with the Chinese Children Cancer Group, St. Jude researchers analyzed data from over 7,600 pediatric patients treated for acute lymphoblastic leukemia (ALL). They demonstrated that assessing MRD levels on day 19 of induction therapy helped refine risk classification and guide treatment intensities. Patients with negative MRD had improved event-free survival, while those with higher MRD benefited from intensified therapy. The findings validate results from St. Jude Total Therapy studies 15 and 16. 

“Our simple diagnostic assay has the potential to enhance precision medicine by identifying more patients who can be cured with conventional therapies,” explained senior author Ching-Hon Pui, MD, St. Jude Department of Oncology. “This study underscores the value of international collaboration and large-scale patient data in advancing treatment strategies that can benefit children worldwide.” 

Read more